Navigation Links
Sending Real-Money Stipend Payments, a Critical Piece of the Clinical Trial Puzzle at DIA 2013
Date:6/20/2013

Vancouver, BC (PRWEB) June 20, 2013

Chexx Inc., a company that specializes in issuing and sending stipend payments to clinical trial patients around the world, announced today that they will be exhibiting at the DIA 49th Annual Meeting, June 24-26, 2013 in Boston. DIA 2013 will provide an invaluable forum for professionals involved in the discovery, development, and life-cycle management of pharmaceuticals, medical devices, and related products. The event will also include discussion of current and evolving areas such as comparative effectiveness research, health outcomes, and drug/device combination products. As a key international payments provider in the clinical trial space, Chexx Inc. will be on the floor at booth 747, arming attendees with information on how proper payment method plays a role in developing strong relationships with clinical trial participants, increasing goodwill and patient retention.

Chexx Inc. enables research companies to send real-money stipends by international check, EFT or preloaded credit cards in virtually every corner of the globe. “Chexx Inc.’s proven payment disbursement solutions are a powerful tool in strengthening patient relationships in markets around the globe,” says Peter Sampson, VP of Corporate Development for Chexx Inc., “We’re pleased to provide affordable payment options in emerging markets like India, Brazil, Mexico and Malaysia. Sponsors and CROs who want to give their participants the luxury of choice will want to learn about QuickDraw, which allows patients to decide how and where they will be paid.”

The Annual Meeting is intended to strengthen professionals’ understanding of the value of cross-discipline integration and to foster innovation for better health outcomes. Attendees will join more than 7,000 life sciences professionals at all levels and across all disciplines involved in the discovery, development, and life cycle management of medical products all with a common goal to foster innovation that will lead to the development of safe and effective medical products and therapies to patients.

About Chexx Inc.:

Chexx Inc. serves the payment disbursement needs of clinical trial companies, market research companies, international payroll, sales organizations and affiliate managers around the world. For over 17 years they have specialized in providing timely, convenient and cost-effective payouts with excellent results. Chexx Inc. maintains a large network of regional banks to provide payment coverage in over 200 countries. Considerable resources are focused on technical integration and relationship management with each banking partner, resulting in stable global coverage and built in redundancy in key regions.

Read the full story at http://www.prweb.com/releases/2013/6/prweb10856695.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Button Batteries Sending More Kids to ER: Study
2. Sending sexually explicit photos by cell phone -- more common among teens than you might think
3. Synthetic Pot Sending Thousands of Young People to ER: Report
4. Revised geographic adjustments could improve accuracy of Medicare payments, will not solve access, quality problems
5. Awards to 5 IU School of Medicine physicians address critical need for geriatricians
6. Night Staffing With Critical Care Docs May Lower ICU Death Rates
7. Antidepressant use associated with increased mortality among critically ill patients?
8. B2B e Trader is Addressing the Critical Needs of Local Businesses by Lauching the New Shop Small Business Directory
9. US Drug Watchdog Says Its Critical All DePuy Pinnacle Hip Implant Recipients Know The Symptoms Of A Failure And They Offer The Names Of The Best Attorneys For Victims
10. Supporting patient autonomy is critical to improving health
11. ASH launches multi-million-dollar grant program to support critical blood disease research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... “Finn Mouseson”: ... take precedence in an average life. This mouse sets out on a journey that ... heart. “Finn Mouseson” is the creation of newly published author and illustrator, Melody Gersonde-Mickelson, ...
(Date:9/20/2017)... ... ... “The Financial Favor of God; Second Edition”: a personal and exquisite recipe ... creation of published author, Brooks Rathell. , “We typically hear about the favor of ... financial favor of God. Not only does it exist, but it is meant for ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, ... marketing leader, Denise Flannery, to its strategic advisory and client development team. ... will work with clients across different industries to develop and implement market-justified strategies, ...
(Date:9/19/2017)... ... 2017 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Swirl: A Wine Tasting Event series on Thursday, October 26, 2017. Hosted at ...
(Date:9/19/2017)... MD (PRWEB) , ... September 19, 2017 , ... ... the Society of Professional Benefit Administrators (SPBA) hosted “Expanding Your Success” ... for SPBA Members as it focused on best practices for third party administrators ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... 12, 2017  ValGenesis Inc., the global leader ... pleased to announce the appointment of Dr. ... Board of Directors and Chairman of Advisory Board ... science companies to manage their entire validation lifecycle ... in this process. Furthermore, ValGenesis VLMS enables rigorous ...
(Date:9/9/2017)... Sept. 9, 2017  Eli Lilly and Company (NYSE: ... secondary endpoint data for lasmiditan, an investigational, oral, first-in-class ... statistically significant improvements compared to placebo in the Phase ... at the 18th Congress of the International Headache Society ... "The data presented today demonstrate lasmiditan,s potential to reduce ...
(Date:9/7/2017)... 7, 2017 Caris Life Sciences, a ... the promise of precision medicine, today announced results ... of its molecular profiling approach in guiding therapeutic ... profiling plus (CGP+) with Caris Molecular Intelligence ® ... a molecular level, leading to more therapeutic options ...
Breaking Medicine Technology: